Short Interest in Nukkleus Inc. (NASDAQ:DFNS) Increases By 159.3%

Nukkleus Inc. (NASDAQ:DFNS) was the target of a large increase in short interest in June. As of June 15th, there was short interest totaling 12,709,157 shares, an increase of 159.3% from the May 31st total of 4,901,184 shares. Currently, 27.1% of the shares of the stock are sold short. Based on an average daily trading volume, of 38,610,141 shares, the days-to-cover ratio is currently 0.3 days.

Analysts Set New Price Targets

DFNS has been the subject of several recent analyst reports. Wall Street Zen lowered Nukkleus from a “hold” rating to a “sell” rating in a research note on Saturday, April 18th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Nukkleus in a report on Thursday, June 18th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has a consensus rating of “Sell”.

More Nukkleus News

Here are the key news stories impacting Nukkleus this week:

• Positive Sentiment: Zacks Research’s longer-term forecast for Nukkleus turns profitable by FY2028-FY2030, with estimates of $0.01, $0.03, and $0.06 per share, which suggests analysts see a path to eventual earnings growth. Zacks Research EPS estimates for Nukkleus
• Neutral Sentiment: Zacks Research also issued near-term estimates showing continued losses in 2026, including Q2 at ($0.05), Q3 at ($0.04), and Q4 at ($0.03) per share, along with a FY2026 loss estimate of ($0.99) per share, reinforcing that profitability is still distant. Zacks Research EPS estimates for Nukkleus
• Negative Sentiment: Short interest rose sharply in mid-June to 12.7 million shares, with about 27.1% of the float sold short, signaling bearish sentiment and potential selling pressure on the stock. Short interest update for Nukkleus

Institutional Trading of Nukkleus

A number of hedge funds and other institutional investors have recently made changes to their positions in DFNS. BNP Paribas Financial Markets bought a new position in shares of Nukkleus in the second quarter valued at about $56,000. Price T Rowe Associates Inc. MD bought a new stake in Nukkleus during the 4th quarter worth about $57,000. GM Advisory Group LLC acquired a new stake in Nukkleus in the 4th quarter valued at about $56,000. Millennium Management LLC acquired a new stake in Nukkleus in the 4th quarter valued at about $60,000. Finally, Ausdal Financial Partners Inc. bought a new position in shares of Nukkleus in the third quarter worth about $105,000. 12.47% of the stock is currently owned by institutional investors and hedge funds.

Nukkleus Price Performance

Shares of DFNS opened at $0.17 on Monday. The company has a market capitalization of $16.17 million, a P/E ratio of -0.06 and a beta of -6.00. Nukkleus has a one year low of $0.16 and a one year high of $15.59. The business’s 50 day simple moving average is $0.38 and its 200-day simple moving average is $1.76. The company has a debt-to-equity ratio of 0.07, a current ratio of 0.25 and a quick ratio of 0.21.

Nukkleus (NASDAQ:DFNS) last released its quarterly earnings results on Wednesday, May 20th. The company reported ($1.14) earnings per share for the quarter. The company had revenue of $3.65 million during the quarter. As a group, sell-side analysts predict that Nukkleus will post -0.99 EPS for the current fiscal year.

Nukkleus Company Profile

Nukkleus Inc, a financial technology company, provides blockchain-enabled technology solutions worldwide. It focuses on providing software and technology solutions for retail foreign exchange trading industry. The company provides transactions platform for dealing and risk management services. It also offers cross-border payment and transactions solutions and blockchain-enabled financial services solutions to institutional investors. In addition, the company provides software, technology, customer sales and marketing, and risk management technology hardware and software solutions.